NWBO
Aunque hace mucho tiempo que conozco esta empresa, estoy repasando las news referentes al ensayo de DCVAX-L para el GBM, cuyos resultados de Fase III se esperan para primeros de septiembre...
Os paso el link, por si a alguien le interesa.....lo cierto es que este tipo de cáncer es muy mortifero....he vivido el caso de un conocido, que era Mosso d'esquadra, que falleció con 40 y pico años....
https://nwbio.com/clinical-trials/dcvax-l-phase-iii-for-gbm-brain-cancer/ Algunos extractos....
"With full standard of care treatment for GBM today, including surgery, radiation and chemotherapy, the median time from surgery to remove the initial tumor to the time of tumor recurrence is just 6.9 months, and median survival is just 14.6 months. There has been very little improvement in clinical outcomes for GBM patients in the last 30 years. The incidence of GBM appears to be on the rise, for unknown reasons, and there is an urgent need for new and better treatments. "
"We, together with our collaborator, Dr. Linda Liau, conducted two prior Phase I/II clinical trials at UCLA with DCVax-L for GBM brain cancer. Those trials consisted of 39 patients, including 20 patients with newly diagnosed GBM and 19 patients recurrent GBM and other gliomas. The newly diagnosed patients who received DCVax in addition to standard of care treatment typically did not have tumor recurrence for a median of approximately 2 years (more than triple the usual time with standard of care treatments), and they survived for a median of approximately 3 years (about 2½ times the usual period of survival with standard of care treatment).
Furthermore, a substantial percentage of patients who received DCVax-L in the prior Phase I/II clinical trials have continued in a “long tail” of survival far beyond even the 3 year median survival. As of the latest long-term data update in July, 2011, 33% of the patients had reached or exceeded 4 years’ median survival and 27% had reached or exceeded 6 years’ median survival. As of this year, 2 of the Phase I/II clinical trial patients have exceeded 10 years’ survival (compared with 14.6 months’ median survival with full standard of care treatment today). "
"
We are currently conducting a 348-patient double blind, randomized, placebo controlled Phase III clinical trial with DCVax-L for newly diagnosed GBM. The primary endpoint of the trial is “Progression Free Survival,” meaning the length of time that a patient continues without disease progression (i.e., recurrence of the tumor). Secondary endpoints include overall survival and other measures.
The trial is under way at 50+ sites (medical centers) across the US. The sites and the eligibility criteria are listed in the profile of the trial at
ClinicalTrials.gov. The trial is also under way in Europe. The lead site is Kings College Hospital in London. Approximately 30 trial sites are also in varying stages of preparation in the U.K. and Germany. "
Por cierto, que nadie se tome estos posts como un pumpeo ni ninguna recomendacion de compra, sino como información compartida. Reïtero el alto riesgo de que salgan malos resultados del ensayo, y que el valor se hunda un 80%. Por ese motivo, sólo llevo 7.500 títulos a 0,31317$.
Un saludo, muchos aciertos y paciencia con este día tan rojo.....
Edito: por cierto, para el caso que el ensayo resultara positivo, posiblemente afectaría negativamente a otra empresa que tengo en cartera, DMPI, y que también está con ensayos para el GBM, que vna más atrasados, concretamente, en Fase II....
https://www.delmarclinicaltrials.com/
